Circulating Immune Checkpoint Panel (17-Plex)
Indications: Use this panel to investigate T cell activation and exhaustion, and to provide supportive information for assessing the potential suitability of checkpoint inhibitor therapies in cancer and autoimmune conditions.
ANALYTES / BIOMARKERS
BTLA, CD27, CD28, CD40, CD80/B7-1, CD86/B7-2, CTLA-4, GITR, GITRL, HVEM, ICOS, LAG-3, PD-1, PD-L1, PD-L2, TIM-3, TLR-2
TURNAROUND-TIME (TAT)
1-5 Days
SAMPLE STABILITY
Samples collected for immune-related biomarkers are stable for approximately 1 year if kept frozen (-80˚C preferred). Samples that are left at room temperature beyond 30 minutes during sample collection or are stored at 4˚C are not stable and are not acceptable unless they are processed in BD P-100 tubes.
PROCEDURE / TECHNIQUE
Luminex® 100/200 (Addressable LASER Bead Immunoassay)
REFERENCE RANGE
Available for plasma-EDTA, serum, and CSF.
CLINICAL ASSOCIATIONS
Indications: Use this test to identify relevant therapy targets, determine disease mechanisms, and diagnose or monitor the following conditions associated with immune regulation and inflammation:
Checkpoint proteins such as PD-1, PD-L1, and CTLA-4 are central to cancer immunotherapy and immune regulation. Measuring both circulating and membrane-associated checkpoint molecules helps clinicians identify immune exhaustion, monitor response to checkpoint inhibitor therapy, and evaluate immune-related adverse events.
Clinicians: Please check with your State Agency to determine if additional licensure or registration requirements may apply.
The interpretation of these test results should be correlated with clinical findings and other diagnostic tests. Cytokine levels can vary due to many biological, physiological, and diurnal factors; their clinical significance must be assessed by a qualified healthcare professional. This information is not intended to be used as the sole basis for diagnosis or treatment decisions.